Table 1 Clinical, technical and dosimetric data

Age (year)

77

[47–84]

Tumour size (mm)

25

[9–32]

Pre-op IPSS

2

[0–18]

Pre-op IIEF5

16

[5–25]

Time interval S/B (months)

120

[18–364]

Follow-up (months)

27

[5.1 - 83]

Total delivered dose (Gy)

38.5

[34–43]

EQD2_αβ3 (Gy)

57.5

[47–68]

EQD2_αβ10 (Gy)

46

[41–54]

Dose/f (Gy)

4

[3.5 - 4.5]

# of fractions

9

[7–10]

# needles

9

[3–12]

# plans

3

[3]

CTV (cc)

12.1

[4–42]

D90 (%)

106

[83–118]

V100 (%)

93

[78–99]

V150 (%)

40.5

[29–57]

V200 (%)

15

[11–22]

DHI

0.5

[0.46 - 0.67]

D10u (%)

126

[59–217]

D30u (%)

115

[27–177]